Orexigen Therapeutics Inc (NASDAQ:OREX)
| 6.45 Data as of May 24 |  -0.03 / -0.46%Today’s Change | 3.10 Today|||52-Week Range 7.73 | +22.85% Year-to-Date |
Latest OREX News | Press Releases
| Commit To Purchase Orexigen Therapeutics At $3, Earn 23.3% May 23 / TheStreet.com | 5 Stocks Under $10 Set to Soar May 23 / TheStreet.com |
Today’s Trading
| Previous close | 6.48 |
| Today’s open | 6.46 |
| Day’s range | 6.30 - 6.47 |
| Volume | 833,181 |
| Average volume (3 months) | 1,122,911 |
| Market cap | $613.3M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/24/2013
Growth & Valuation
| Earnings growth (last year) | -118.97% |
| Earnings growth (this year) | +38.21% |
| Earnings growth (next 5 years) | +15.00% |
| Revenue growth (last year) | -22.07% |
| P/E ratio | NM |
| Price/Sales | 108.34 |
| Price/Book | 7.25 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CCXIChemoCentryx Inc | -0.02 | -0.14% |
| ICPTIntercept Pharmaceut... | +0.19 | +0.56% |
| LGNDLigand Pharmaceutica... | -0.48 | -1.72% |
| ARRYArray Biopharma Inc | +0.19 | +3.36% |
Data as of 4:00pm ET, 05/24/2013
Financials
| Next reporting date | August 8, 2013 |
| EPS forecast (this quarter) | -$0.19 |
| Annual revenue (last year) | $3.4M |
| Annual profit (last year) | -$90.1M |
| Net profit margin | -2,628.18% |
Profile
Sector Health Technology |
Industry Biotechnology |
Chairman Eckard Weber, MD |
President, Chief Executive Officer & Director Michael A. Narachi, MBA |
Corporate headquarters La Jolla, California |
Forecasts
